CN110904072A - Novel phospholipase D and method for preparing functional phospholipid by using same - Google Patents
Novel phospholipase D and method for preparing functional phospholipid by using same Download PDFInfo
- Publication number
- CN110904072A CN110904072A CN201911149105.2A CN201911149105A CN110904072A CN 110904072 A CN110904072 A CN 110904072A CN 201911149105 A CN201911149105 A CN 201911149105A CN 110904072 A CN110904072 A CN 110904072A
- Authority
- CN
- China
- Prior art keywords
- phospholipase
- ala
- activity
- gene
- pldmd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/001—Amines; Imines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/06—Alanine; Leucine; Isoleucine; Serine; Homoserine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/44—Preparation of O-glycosides, e.g. glucosides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6436—Fatty acid esters
- C12P7/6445—Glycerides
- C12P7/6481—Phosphoglycerides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
- C12Y301/04004—Phospholipase D (3.1.4.4)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention belongs to the technical field of enzyme genetic engineering, and particularly relates to a phospholipase D mutant with improved specific enzyme activity obtained by in-vitro directed evolution through an error-prone PCR technology and an overlapped PCR technology, then high-activity phospholipase D genes are respectively expressed in a bacillus subtilis expression system, a bacillus amyloliquefaciens expression system and a bacillus licheniformis expression system, and after expression, the specific enzyme activity of the high-activity phospholipase D is detected to be improved by 500% at most compared with that of wild-type phospholipase D. The highest values of the fermentation enzyme activities of the high-activity phospholipase D in a bacillus subtilis expression system, a bacillus licheniformis expression system and a bacillus amyloliquefaciens expression system are 319.1U/mL, 952.2U/mL and 1304.5U/mL respectively, and phosphatidic acid, phosphatidylserine, phosphatidylethanolamine, phosphatidylglycerol and phosphatidylinositol are effectively prepared by using the high-activity phospholipase D.
Description
The technical field is as follows:
the invention belongs to the technical field of enzyme genetic engineering, and particularly relates to a phospholipase D mutant with improved specific enzyme activity obtained by in vitro directed evolution through an error-prone PCR (polymerase chain reaction) technology and an overlapped PCR technology, and provides a method for preparing functional phospholipid through catalysis of high-activity phospholipase D.
Background art:
phospholipase D (PLD) is widely available and is mainly distributed in animals, plants and microorganisms. PLD can catalyze two reactions: first, hydrolyzing phospholipids to produce phosphatidic acid and hydroxyl compounds; secondly, when another hydroxyl group-containing compound is present, it can be catalyzed to bind to the base of the phospholipid to form a new phospholipid, which is a transphosphorylation reaction or a base exchange reaction of PLD. Especially important in both reactions is the transphosphorylation esterification of PLD, which catalyzes the synthesis of other rare phospholipids from Phosphatidylcholine (PC) which is abundant in nature, such as Phosphatidic Acid (PA), Phosphatidylglycerol (PG), Phosphatidylserine (PS), Phosphatidylethanolamine (PE), Phosphatidylinositol (PI), etc. Therefore, phospholipases and their catalytic reactions are currently an active area of research.
PA is a simple and common phospholipid which promotes mitosis, formation of superoxide in cells, causes contraction of muscles, promotes secretion of hormones, induces platelet aggregation, and the like. PG is a natural rare phospholipid. PG not only can reduce pulmonary surface tension and maintain the stability of alveolar structure and function, but also can be used as an anticancer drug carrier to carry out targeted therapy on focus. PS is one of phospholipids with a low natural content, and can improve brain cell activity, improve brain function, and repair brain injury. PE is a common phospholipid, wherein high-purity PE has great potential in improving human memory and enhancing brain function, and simultaneously has the functions of maintaining and improving cognition. PI accounts for about 5-10% of total phospholipids of cells, and plays an important role in cell morphology, metabolic regulation, signal transduction and various physiological functions of cells.
However, these rare phospholipids cannot be completely synthesized by the human body itself. The current preparation of rare phospholipids is by solvent extraction, chemical synthesis and enzymatic conversion. The adoption of the solvent extraction method is questioned due to the safety, the chemical synthesis method has high cost and complex process, the purity and the yield are to be improved, and the enzymatic conversion method has the advantages of mild reaction conditions, easy control of the reaction, high efficiency and simplicity, so that the method is more and more concerned.
Compared with PLD of animal and plant origin, PLD of microbe has better transphospholipid activity, wider substrate specificity and stronger substrate tolerance. The types of PLD-producing microorganisms reported so far are mainly Streptomyces (Streptomyces), Escherichia coli (Escherichia coli), Salmonella (Salmonella), Pseudomonas (Pseudomonas), and the like. Of these, PLD from Streptomyces is the most reported, and they have better hydrolytic and transphospholipid activities. However, because streptomyces has a long fermentation period and complicated culture conditions, it is necessary to produce high-activity PLD by heterologous expression.
Directed evolution, also known as irrational design of enzymes, is to obtain mutants with certain specific excellent properties in a short time by simulating evolution mechanisms such as random mutation, recombination and the like occurring in natural evolution without specifying structural information and catalytic mechanism of enzyme proteins and by applying directional pressure in later screening. The error-prone PCR used in the present invention is a classical method in irrational design, and the principle is to adjust the mutation frequency in PCR reaction by changing the PCR reaction conditions, to reduce the inherent mutation sequence tendency of polymerase, to increase the diversity of mutation spectrum, to make the wrong bases randomly doped into the amplified gene at a certain frequency, to obtain the random mutated DNA population, and finally to clone the mutated gene with a suitable vector.
Site-directed mutagenesis, also known as rational design, is the insertion, deletion or substitution of a nucleotide sequence of a certain length into a known DNA sequence, and is a very useful means in gene research work due to its rapid and efficient improvement of the properties and characterization of a target protein expressed by DNA. The overlapping PCR technology used by the invention is one of site-directed mutagenesis technologies, and the technology can simply and quickly carry out in-vitro gene splicing on two or more gene segments through terminal complementation and overlapping extension. The overlapping PCR technology can obtain products which are difficult to obtain by means of restriction enzyme digestion, is convenient and quick, and has unique advantages in site-directed mutagenesis of large-fragment genes, gene fragment deletion and chimeric connection of a plurality of coding sequences.
Bacillus subtilis belongs to gram-positive bacteria. The bacillus subtilis expression system has the following advantages: 1. can efficiently secrete various proteins; 2. many Bacillus subtilis strains have a long history of use in the fermentation industry, are nonpathogenic, and do not produce any endotoxin; 3. the research on the background of the genetics of the microorganism of the genus bacillus is clear, the growth is rapid, and no special requirements on nutrient substances are required; 4. codon preference is not obvious; 5. the fermentation process is simple, the bacillus subtilis belongs to aerobic bacteria, anaerobic fermentation equipment is not needed, and after the fermentation is finished, fermentation liquor and bacterial thalli are simply separated, so that the separation, purification and recovery stages of target protein can be carried out; 6. has stress resistance, and can be used for producing various thermostable enzyme preparations. The bacillus subtilis expression system becomes the most important tool and model for modern molecular biology research, and is an ideal tool for expressing exogenous genes.
Bacillus licheniformis belongs to gram-positive bacteria. The bacillus licheniformis expression system has the following advantages: 1. the protein is directly secreted into an extracellular culture medium without accumulation, thereby being beneficial to downstream recovery and purification of the protein and reducing the operation cost of the whole production chain; 2. the extracellular protein has large secretion amount and higher growth temperature, and is suitable for being used as host bacteria for industrial production; 3. as a unicellular organism, the culture medium can reach very high cell density in the fermentation process, is relatively simple, has low cost and high yield, and meets the requirements of industrial production.
Bacillus amyloliquefaciens is a gram-positive bacterium. The bacillus amyloliquefaciens expression system has the following advantages: 1. the secondary metabolite is rich, and can generate various antibacterial substances such as antibacterial protein, lipopeptide, polyketide and the like; 2. the protein produced by the bacillus amyloliquefaciens has good hydrophilicity, stability and high activity; 3. the bacillus amyloliquefaciens can produce various physiologically active substances and amino acid substances; 4. in the bacillus amyloliquefaciens, the number of genes related to the synthesis of proteins and enzyme antibacterial substances is small, and the gene recombination and expression are facilitated; 5. the bacillus amyloliquefaciens has a wide antibacterial spectrum, has the advantages of no pollution, no drug resistance, contribution to human body safety and the like, and has a good development prospect.
In the invention, the high-activity phospholipase D mutant genes are expressed in a bacillus subtilis expression system and a bacillus licheniformis and bacillus amyloliquefaciens expression system to respectively obtain high-activity phospholipase D free expression recombinant strains of the bacillus subtilis, the bacillus licheniformis and the bacillus amyloliquefaciens, the high-activity phospholipase D can be obtained by corresponding treatment after the recombinant strains are fermented, and the high-activity phospholipase D is purified and then reacts with a substrate to prepare the functional phospholipid through catalysis.
The invention content is as follows:
the invention aims to provide a novel phospholipase D mutant and a method for preparing functional phospholipid by using the same.
In order to achieve the above purpose, one of the technical solutions provided by the present invention is: a Streptomyces antibioticus (Streptomyces antibioticus) genome preserved in the laboratory of the applicant is used as a template, a phospholipase D wild-type gene pld (shown as SEQ ID NO: 1) is cloned, a recombinant vector is constructed through enzyme digestion, connection and the like, random mutation is introduced into the gene through an error-prone PCR technology, and a mutation library is established to screen mutants capable of obtaining high phospholipase D yield. Phospholipase D mutants are based on SEQ ID No: 2, wherein at least one of the amino acids at positions 84, 153, 270, 316 and 452 is replaced with the following amino acid: at position 84: D84I; 153 th bit: N153I; 270 th position: G270F; 316 th bit: P316W; at bit 452: A452F. Then, single mutation point genes are subjected to chimeric connection by an overlapping PCR technology to obtain a combined mutant (see a comparison table 1).
In order to achieve the above purpose, the second technical solution provided by the present invention is: reconstructing a recombinant vector from the mutant gene, performing high-efficiency expression in bacillus subtilis, bacillus licheniformis and bacillus amyloliquefaciens to obtain a recombinant strain for producing the high-activity phospholipase D, and performing fermentation, extraction and other technologies to obtain the high-activity phospholipase D.
The host cells for expressing the phospholipase D mutant are respectively bacillus subtilis, bacillus licheniformis and bacillus amyloliquefaciens, and the expression vector is pBSA 43;
preferably, the bacillus subtilis is bacillus subtilis WB 600;
preferably, the bacillus licheniformis is bacillus licheniformis TCCC 11965;
preferably, the bacillus amyloliquefaciens is bacillus amyloliquefaciens CGMCC No. 11218;
in order to achieve the above purpose, the third technical solution provided by the present invention is: the phospholipase D mutant is applied to preparing phospholipid, particularly PA, PS, PE, PG and PI.
The following definitions are used in the present invention:
1. nomenclature for amino acid and DNA nucleic acid sequences
The accepted IUPAC nomenclature for amino acid residues is used, in the form of the single letter code. DNA nucleic acid sequences employ the accepted IUPAC nomenclature.
2. Identification of phospholipase D mutants
"amino acid substituted by original amino acid position" is used to indicate a mutated amino acid in the phospholipase D mutant. As with D84I, the amino acid at position 84 is replaced by D for I for the wild-type phospholipase D. The numbering of positions corresponds to SEQ ID NO: 2, amino acid sequence number of phospholipase D. Nucleotide changes are also denoted by "original nucleotide position substituted nucleotide" and the position numbering corresponds to that of SEQ ID NO:1, nucleotide sequence number of wild-type phospholipase D.
In the present invention, pld represents the wild-type phospholipase D, and the amino acid sequence is the original sequence (shown in SEQ ID NO: 2). Each of the mutants obtained on the basis of pld was represented by pldm plus AxB, A, B represents amino acids, x is 84, 153, 270, 316, 452, respectively, where pldmD84I represents a mutant in which amino acid 84 was replaced by D to I, pldmN153I represents a mutant in which amino acid 153 was replaced by N to I, pldmG270F represents a mutant in which amino acid 270 was replaced by G to F, pldmP316W represents a mutant in which amino acid 316 was replaced by P to W, and pldmA452F represents a mutant in which amino acid 452 was replaced by a to F; AxB may also be AxmB/…/CxnD form, which represents a combinatorial mutant of several positions, such as pldmD84I/N153I, which represents a mutant in which amino acid 84 is replaced by D to I and amino acid 153 is replaced by N to I (wherein, D: Asp; I: Ile; N: Asn; G: Gly; F: Phe; P: Pro; W: Trp; A: Ala). The coding gene of each mutant is shown in italics in amino acid representation, for example, the coding gene of mutant pldmD84I is pldmD 84I.
In the present invention, the combinatorial mutation of amino acids comprises the following:
pldmD84I/N153I、pldmD84I/G270F、pldmD84I/P316W、pldmD84I/A452F、pldmN153I/G270F、pldmN153I/P316W、pldmN153I/A452F、pldmG270F/P316W、pldmG270F/A452F、pldmP316W/A452F、pldmD84I/N153I/G270F、pldmD84I/N153I/P316W、pldmD84I/N153I/A452F、pldmD84I/G270F/P316W、pldmD84I/G270F/A452F、pldmD84I/P316W/A452F、pldmN153I/G270F/P316W、pldmN153I/G270F/A452F、pldmG270F/P316W/A452F、pldmN153I/P316W/A452F、pldmD84I/N153I/P316W/A452F、pldmD84I/N153I/G270F/P316W、pldmD84I/N153I/G270F/A452F、pldmD84I/G270F/P316W/A452F、pldmN153I/G270F/P316W/A452F、pldmD84I/N153I/G270F/P316W/A452F；
table 1: comparison table of mutation sites
The experimental steps of the invention are as follows:
1. a process for obtaining a gene encoding a high-activity phospholipase D mutant comprises the following steps:
wild phospholipase D gene (shown in SEQ ID NO. 1) from Streptomyces antibioticus (Streptomyces antibioticus) is connected with a vector pET22b to construct a recombinant plasmid pET22b-pld, random mutation is introduced into the phospholipase D gene by using error-prone PCR technology to construct a recombinant plasmid pET22b-pldmAxB, and mutant encoding genes pldmD84I, pldmN153I, pldmG270F, pldmP316W and pldmA452F with higher phospholipase D yield are obtained by establishing a mutation library and screening. The multiple mutation point genes are subjected to chimeric ligation by overlap PCR to obtain the high-activity phospholipase D mutant coding genes pldmD 84/N153, pldmD 84/G270, pldmD 84/P316, pldmD 84/A452, pldmN 153/G270, pldmN 153/P316, pldmN 153/A452, pldmG 270/P316, pldmG 270/A452, pldmP 316/A452, pldmD 84/N153/G270, pldmD 84/N153/P316, pldmD 84/N153/A452, pldmD 84/G270/P316, pldmD 84/G270/A452, pldmD 84/P316/A153/A452, pldmN 153/G270/P316, pldmN 153/G270/A452, pldmG 153/P316, pldmG/P270/A452, pldmG 84/P153/P452, pldmG/P153/P270/P452, pldmG/P270/P452, pldmD 84/P153/P452, pldmD/P153/, pldmD 84I/N153I/G270F/P316W/A452F.
2. The bacillus subtilis recombinant strain containing the high-activity phospholipase D gene and the process for preparing the high-activity phospholipase D by using the bacillus subtilis recombinant strain comprise the following steps:
(1) carrying out enzyme digestion on pET22b-pldmAxB containing the coding gene of the high-activity phospholipase D mutant, and connecting the obtained coding gene of the high-activity phospholipase D mutant with a vector escherichia coli-bacillus subtilis shuttle plasmid pBSA43 to obtain a new recombinant vector;
(2) and (3) transforming the recombinant vector into the bacillus subtilis WB600 to obtain a recombinant strain, and then fermenting the recombinant strain to obtain the high-activity phospholipase D.
(3) Then fermenting to prepare the high-activity phospholipase D.
3. The bacillus licheniformis recombinant strain containing the high-activity phospholipase D gene and the process for preparing the high-activity phospholipase D by the bacillus licheniformis recombinant strain comprise the following steps:
(1) carrying out enzyme digestion on pET22b-pldmAxB containing the coding gene of the high-activity phospholipase D mutant, and connecting the obtained coding gene of the high-activity phospholipase D mutant with an expression vector Escherichia coli-Bacillus licheniformis shuttle plasmid pBSA43 to obtain a new recombinant vector;
(2) transforming the recombinant vector into bacillus licheniformis TCCC11965, and screening the obtained recombinant strain with geneticin and determining the enzyme activity of phospholipase D to obtain a high-yield strain of high-activity phospholipase D;
(3) then fermenting to prepare the high-activity phospholipase D.
4. The bacillus amyloliquefaciens recombinant strain containing the high-activity phospholipase D gene and the process for preparing the high-activity phospholipase D by using the bacillus amyloliquefaciens recombinant strain comprise the following steps:
(1) carrying out enzyme digestion on pET22b-pldmAxB containing the coding gene of the high-activity phospholipase D mutant, and connecting the obtained coding gene of the high-activity phospholipase D mutant with an expression vector Escherichia coli-Bacillus amyloliquefaciens shuttle plasmid pBSA43 to obtain a new recombinant vector;
(2) transforming the recombinant vector into bacillus amyloliquefaciens CGMCC No.11218, and screening the obtained recombinant strain by using geneticin and measuring the enzyme activity of phospholipase D to obtain a high-yield strain of high-activity phospholipase D;
(3) then fermenting to prepare the high-activity phospholipase D.
Has the advantages that:
1. the present invention utilizes error-prone PCR technology to introduce random mutations into genes, screens 5 highly active phospholipase D mutants and genes by creating a mutation library, and utilizes overlap PCR technology to perform mutation point combination on the phospholipase D mutant genes (pldmD 84/N153, pldmD 84/G270, pldmD 84/P316, pldmD 84/A452, pldmN 153/G270, pldmN 153/P316, pldmN 153/A452, pldmG 270/P316, pldmG 270/A452, pldmP 316/A452, pldmD 84/N153/G270, pldmD 84/N153/P316, pldmD 84/N153/A452, pldmD 84/G270/P316, pldmD 84/G270/A452, pldmD 84/P452/A452, pldmD 84/P153/P316, pldmN 270/P316, pldmN 153/G270/P452, pldmD 153/P153/A452, pldmD 84/P153/A452, pldmD 153/P153/A452, pldmD 84/P452, pldmD/P153/A452, pldmD/P452, pldmD 84/A452, pldmD/P153/A452, pldmD/P452, pldmD84I/N153I/G270F/A452F, pldmD84I/G270F/P316W/A452F, pldmN153I/G270F/P316W/A452F, pldmD84I/N153I/G270F/P316W/A452F), and further expressing the phospholipase D with high activity.
2. According to the invention, a bacillus subtilis expression system, a bacillus licheniformis expression system and a bacillus amyloliquefaciens expression system are respectively used, and the highest values of the fermentation enzyme activities of the high-activity phospholipase D in the expression systems are 319.1U/mL, 952.2U/mL and 1304.5U/mL respectively, which are respectively improved by 480%, 425% and 500% compared with the wild type.
3. The conversion rates of PA, PS, PE, PG and PI produced by adopting high-activity phospholipase D are respectively 93%, 79.3%, 53.9%, 60.1% and 32.1%.
Description of the drawings:
FIG. 1 is a PCR amplification electrophoretogram of wild-type phospholipase D gene of the present invention
Wherein: m is DNA Marker, 1 and 2 are phospholipase D genes respectively;
FIG. 2 is a restriction enzyme digestion verification diagram of recombinant plasmid pBSA43-pldmD84I in Bacillus subtilis of the present invention
Wherein: m is DNA Marker, 1 is recombinant plasmid pBSA43-pldmD84I through EcoR I and Not I double enzyme cutting map;
FIG. 3 shows the restriction enzyme digestion verification of recombinant plasmid pBSA43-pldmD84I in Bacillus licheniformis of the present invention
Wherein: m is DNA Marker, 1 is recombinant plasmid pBSA43-pldmD84I through EcoR I and Not I double enzyme cutting map;
FIG. 4 shows the restriction enzyme digestion verification of the recombinant plasmid pBSA43-pldmD84I in Bacillus amyloliquefaciens of the present invention
Wherein: m is DNA Marker, 1 is recombinant plasmid pBSA43-pldmD84I through EcoR I and Not I double enzyme cutting map;
FIG. 5 SDS-PAGE of example 7 purified samples;
FIG. 6 SDS-PAGE of example 8 purified samples;
FIG. 7 SDS-PAGE of example 9 purified samples.
The specific implementation mode is as follows:
the technical content of the present invention is further illustrated by the following examples, but the present invention is not limited to these examples, and the following examples should not be construed as limiting the scope of the present invention.
The bacillus licheniformis used in the invention is TCCC11965, which is disclosed in the following parts: development and approval of a CRISPR/Cas9 system for Bacillus licheniformis microorganisms edition [ J ]. International Journal of Biological Macromolecules,2019,122:329-337, currently maintained at the institute of microbial cultures, university of Otsu technology, from which cultures are publicly available.
Example 1: acquisition of wild-type phospholipase D Gene
1. The wild phospholipase D gene is derived from Streptomyces antibioticus (Streptomyces antibioticus), and the genome DNA of the wild phospholipase D gene is extracted.
Wherein the extraction steps of the streptomyces antibiotics genomic DNA are as follows:
(1) a loopful of the bacterium was picked from the plate on which the bacterium was cultured, inoculated in 50mL of an appropriate medium, and cultured at 26 ℃ and 150r/min for 2 to 3 days.
(2) Then 1mL of the culture medium was centrifuged at 8000r/min for 20min in a 1.5mL EP tube, the supernatant was decanted, and resuspended in 200. mu.L of solution I or sterile water.
(3) Adding 20-50 μ L of 50mg/mL lysozyme, and digesting at 37 deg.C for 0.5-1 h.
(4) 100 mu L of 2% SDS solution is added, and the reaction is carried out fully until the bacterial suspension is viscous.
(5) Equal volumes of Tris-equilibrated phenol were added: chloroform-1: 1, mixing evenly, centrifuging at 12000r/min for 5min, and transferring the supernatant to another EP tube.
(6) The extraction was repeated twice until no protein layer appeared, and finally, the extraction was performed once with chloroform of the same volume.
(7) Adding equal volume of isopropanol to precipitate DNA, centrifuging at 12000r/min for 5min, discarding supernatant, washing with 500 μ L75% ethanol for 2 times, and centrifuging at 12000r/min for 5min after each blow-beating.
(8) Placing the EP tube in filter paper or metal bath at 55 deg.C, air drying until no alcohol smell, dissolving with TE buffer solution or sterilized water, and storing at-20 deg.C.
2. Designing amplification primers of a wild phospholipase D gene from the phospholipase D gene, wherein the sequences are as follows:
upstream P1(SEQ ID NO: 5): CCGGAATTCGGCGGACACACCGCC
Downstream P2(SEQ ID NO: 6): AAGGAAAAAAGCGGCCGCGCCCGCCTGGCG
The reaction system for PCR amplification is 50 μ L, and comprises the following components:
| 2×buffer | 25μL |
| dNTPs(2.5mmol/L each) | 2μL |
| upstream primer P1 (20. mu. mol/L) | 5μL |
| Downstream primer P2 (20. mu. mol/L) | 5μL |
| DNA template | 2μL |
| Pyrobest enzyme | 0.5μL |
| ddH2O | 10.5μL |
| Total volume | 50μL |
The setting of the amplification program is as follows: the amplification conditions were: pre-denaturation at 95 ℃ for 10 min; denaturation at 94 ℃ for 30s, annealing at 53 ℃ for 45s, extension at 72 ℃ for 1min for 45s, and reaction for 30 cycles; extension at 72 ℃ for 10 min. The PCR product was subjected to agarose gel electrophoresis to visualize the band of wild-type phospholipase D gene, which was 1527bp (see FIG. 1), and then the PCR product was recovered by a small amount of DNA recovery kit to obtain the wild-type phospholipase D gene, namely pld (shown in SEQ ID NO. 1).
The purified pld and pET22b expression vector are connected, then the recombinant plasmid is transformed into Escherichia coli DH5 α, and the cloning of the wild-type phospholipase D gene on the pET22b vector is successfully verified through two enzyme cutting of EcoR I and Not I.
Example 2: screening of high-Activity phospholipase D Gene
1. Random mutation is carried out based on an error-prone PCR technology to construct novel phospholipase D, and primers are designed as follows:
upstream P1(SEQ ID NO: 5): CCGGAATTCGGCGGACACACCGCC
Downstream P2(SEQ ID NO: 6): AAGGAAAAAAGCGGCCGCGCCCGCCTGGCG
In the error-prone PCR reaction system, error-prone PCR was performed using P1 and P2 as upstream and downstream primers, and pET22b-pld, a recombinant vector in which a wild-type phospholipase D gene was ligated to pET22b, as a template.
The reaction conditions for amplification are as follows:
the amplification conditions were: pre-denaturation at 95 ℃ for 10 min; denaturation at 98 ℃ for 10s, annealing at 53 ℃ for 30s, and extension at 72 ℃ for 1min for 45s reaction for 30 cycles; extension at 72 ℃ for 10 min.
2. Cloning the phospholipase D error-prone PCR product into an expression vector pET22b, and transforming Escherichia coliBL21(DE3) was inoculated into 96-well cell culture plates containing 200. mu.L of LB liquid medium (30. mu.g/mL of Kan) per well, and shake-cultured at 37 ℃ at 200r/min when OD is OD600When the concentration reaches 0.6, IPTG (final concentration is 1mmol/L) is added into each hole, the induction is carried out for 16h at the temperature of 16 ℃, the supernatant is collected after 15min of centrifugation at 4000r/min at the temperature of 4 ℃ to obtain crude enzyme liquid, and then the enzyme activity detection is carried out.
3. Screening of high-Activity phospholipase D Gene
(1) Principle of phospholipase D enzyme activity determination
And performing activity detection by adopting an enzyme-linked colorimetric method, namely catalyzing L- α -lecithin by phospholipase D to generate choline, generating hydrogen peroxide by the choline under the action of choline oxidase, generating a quinonimine chromogenic substance by the hydrogen peroxide, 4-aminoantipyrine and phenol under the action of peroxidase, and having a light absorption value at the wavelength of 500 nm.
The enzyme activity is defined as the amount of enzyme required by phospholipase D to catalyze hydrolysis of L- α -lecithin to release 1.0. mu. mol choline within 1min at pH8.0 and T37 ℃.
(2) High-activity phospholipase D enzyme activity screening method
Lecithin emulsion: 0.345g lecithin, 2mL diethyl ether, 3mL 7.5% Triton X-100, 20mLH2And O, fully and uniformly mixing.
Reaction termination solution: 1M Tris-HCl, 0.5M EDTA, pH 8.0.
Screening phospholipase D:
mu.L lecithin emulsion, 10. mu.L 100mM Tris-HCl, 5. mu.L CaCl were added to a 96-well plate210 μ L of crude enzyme solution (prepared by dissolving in PBS if enzyme powder; and supernatant as enzyme solution after centrifuging if fermentation liquid), reacting in water bath at 37 deg.C for 10min, adding 20 μ L of reaction stop solution, boiling for 5min, and cooling to room temperature. Subsequently, 180. mu.L of 10mM Tris-HCl containing 2U of choline-containing oxidase, 4U of peroxidase, 2mg of 4-antipyrine, 1mg of phenol, 20mg of Triton X-100 was added, reacted at 37 ℃ for 20min, followed by measurement of absorbance at 500 nm.
The blank sample was zeroed by replacing the enzyme solution in the reaction with water.
(3) Phospholipase D enzyme activity assay
Through determination, 5 mutants with higher activity than the wild type are screened, and the sequencing result (Beijing Hua big bioengineering company) shows that 5 phospholipase D variant coding genes are respectively: the enzyme activities of pldmD84I, pldmN153I, pldmG270F, pldmP316W and pldmA452F were respectively increased by 33%, 29%, 46%, 38% and 27% over the phospholipase D encoded by pld.
Example 3: obtaining phospholipase D variants with multiple amino acid mutations on the basis of single amino acid mutation, taking the overlapping PCR technology to perform N153I, G270F, P316W and A452F mutation on the basis of pldmD84I mutant as an example, the final gene sequence is shown as SEQ ID NO: 3, and the final amino acid sequence is shown as SEQ ID NO: 4, respectively.
The specific strategy is as follows: double mutations are first effected on the basis of a single mutation, followed by mutations of the third, fourth and fifth amino acids.
Firstly, mutation of N153I is realized on the basis of D84I, the procedure is consistent with that of example 2, and overlapping primers are designed as follows:
upstream P1(SEQ ID NO. 5): CCGGAATTCGGCGGACACACCGCC
Downstream P2(SEQ ID NO. 6): AAGGAAAAAAGCGGCCGCGCCCGCCTGGCG
Overlapping primer P5(SEQ ID NO. 7): CGGCAAGGTCACGCTCATCGTCGCCTC
Overlapping primer P6(SEQ ID NO. 8): GAGGCGACGATGAGCGTGACCTTGCCG
Overlapping primers P5 and P6 contained a mutation at amino acid residue 153.
PCR amplification was performed using the recombinant plasmid pET22b-pldmD84I, a recombinant vector in which the gene encoding mutant pldmD84I was ligated to pET22b vector as a template;
PCR1, reaction system 50 μ L, consisting of:
| 10×PCR buffer | 5μL |
| dNTPs | 5μL |
| upstream primer P1 | 2μL |
| Downstream primer P6 | 2μL |
| pET22b-pldmD84I | 2μL |
| Pyrobest enzyme | 0.5μL |
| ddH2O | 10.5μL |
| Total volume | 50μL |
PCR2, reaction system 50 μ L, consisting of:
the PCR1 and PCR2 amplification programs were set up as: pre-denaturation at 95 ℃ for 10 min; denaturation at 94 ℃ for 30s, annealing at 53 ℃ for 45s, and extension at 72 ℃ for 45s, and reacting for 30 cycles; extension at 72 ℃ for 10 min.
PCR3, reaction system 46 μ L, consisting of:
| 10×PCR buffer | 5μL |
| dNTPs | 5μL |
| PCR1 product | 2μL |
| PCR2 product | 2μL |
| Pyrobest enzyme | 0.5μL |
| ddH2O | 31.5μL |
| Total volume | 46μL |
The PCR3 amplification program was set up as: pre-denaturation at 95 ℃ for 10 min; denaturation at 94 ℃ for 30s, annealing at 60 ℃ for 45s, and extension at 72 ℃ for 1min45s for 30 cycles; extension at 72 ℃ for 10 min.
PCR4, reaction system 50 μ L, consisting of:
| 10×PCR buffer | 5μL |
| dNTPs | 5μL |
| upstream primer P1 | 2μL |
| Downstream primer P2 | 2μL |
| PCR3 product | 2μL |
| Pyrobest enzyme | 0.5μL |
| ddH2O | 31.5μL |
| Total volume | 50μL |
The PCR4 amplification program was set up as: pre-denaturation at 95 ℃ for 10 min; denaturation at 94 ℃ for 30s, annealing at 53 ℃ for 45s, and extension at 72 ℃ for 1min45s for 30 cycles; extension at 72 ℃ for 10 min.
The PCR product obtained finally was sequenced (Beijing Huada bioengineering Co.), and the amplification resulted in the D84I and N153I double-mutated phospholipase D gene fragment pldmD84I/N153I, with amino acid and base mutation sites as shown in Table 1.
Continuing to perform other mutations, the steps are consistent with those of example 2, all mutant primer sequences are shown in the following table 3, replacing primers according to table 3 on the basis of pldmD84I/N153I according to the steps, sequentially performing point mutation and combined mutation of G270F, P316W and a452F, sending the point mutation and the combined mutation to a sequencing company for sequencing, and finally obtaining 26 strains with high-activity phospholipase D, wherein the steps are respectively as follows: BL/pET 22-pldmD 84/N153, BL/pET 22-pldmD 84/G270, BL/pET 22-pldmD 84/P316, BL/pET 22-pldmD 84/A452, BL/pET 22-pldmN 153/G270, BL/pET 22-pldmN 153/P316, BL/pET 22-pldmN 153/A452, BL/pET 22-pldmG 270/P316, BL/pET 22-pldmG 270/A452, BL/pET 22-pldmP 316/A452, BL/pET 22-pldmD 84/N153/G270, BL/pET 22-pldmD 84/N153/P316, BL/pET 22-pldmD 84/P452/pET 22-pldmD 84/P270/P316, BL/pET 22-pldmD 84/N153/P452, BL/P153/P452, BL/pDMT 22/P270/P452, BL/pDMT 22/P270/P452, BL/P452, BL/pDT 22/pDMT 22, BL/pET 22-pldmN 153/G270/A452, BL/pET 22-pldmG 270/P316/A452, BL/pET 22-pldmN 153/P316/A452, BL/pET 22-pldmD 84/N153/G270/P316, BL/pET 22-pldmD 84/N153/G270/A452, BL/pET 22-pldmD 84/G270/P316/A452, BL/pET 22-pldmN 153/G270/P316/A452, BL/pET 22-pldmD 84/N153/P316/A452.
TABLE 3 overlapping PCR primers
| Mutation site | F-end primer | R-terminal primer |
| N153I | P5:SEQ ID NO.7 | P6:SEQ ID NO.8 |
| G270F | P7:SEQ ID NO.9 | P8:SEQ ID NO.10 |
| P316W | P9:SEQ ID NO.11 | P10:SEQ ID NO.12 |
| A452F | P11:SEQ ID NO.13 | P12:SEQ ID NO.14 |
Example 4: construction of bacillus subtilis high-activity phospholipase D recombinant strain
1. Construction of expression vector pBSA43
An expression vector pBSA43 is obtained by taking an escherichia coli-bacillus subtilis shuttle cloning vector pBE2 as a framework and cloning a strong bacillus constitutive promoter P43 and a levansucrase signal sequence sacB which can ensure that a recombinant protein is directly secreted into a culture medium. It carries AmprAnd KmrThe gene can utilize ampicillin resistance as a selection marker in escherichia coli, and can utilize kanamycin resistance as a selection marker in bacillus subtilis and bacillus licheniformis.
2. Construction of high-Activity phospholipase D expression vector pBSA43-pldmAxB
And carrying out double enzyme digestion on the obtained high-activity phospholipase D gene and the wild-type phospholipase D gene and a bacillus subtilis expression vector pBSA43 respectively, then connecting to construct a recombinant plasmid pBSA43-pldmAxB, transforming to escherichia coli DH5 α competent cells, selecting positive transformants, extracting the plasmid, carrying out enzyme digestion verification and sequencing, and determining that the construction is successful to obtain the recombinant strain pBSA 43-pldmAxB.
3. Expression vector pBSA43-pldmAxB transformation of Bacillus subtilis WB600
Adding 60 mu L of competent cells and 1 mu L (50 ng/. mu.L) of pBSA43-pldmx into a precooled 1mm electric rotating cup, uniformly mixing and carrying out ice bath for 5min, setting parameters (25 mu F, 200 omega, 4.5-5.0ms), shocking once, immediately adding 1mL of recovery medium (LB +0.5mol/L sorbitol +0.5mol/L mannitol), uniformly mixing, absorbing into a 1.5mLEP tube, shaking and culturing for 3h at 37 ℃, centrifuging, reserving 200 mu L of recovery, coating on a resistant LB plate, culturing for 24h at 37 ℃, picking up a transformant, extracting plasmids, and carrying out enzyme digestion verification (pBSA43-pldmD84I enzyme digestion verification is shown in figure 2, and other mutant gene recombination plasmids are shown in figure 2), thus obtaining the AxBb bacillus subtilis recombination strain WB600/pBSA 43-pldmB.
Example 5: construction of bacillus licheniformis high-activity phospholipase D recombinant strain
1. Construction of expression vector pBSA43
An expression vector pBSA43 is obtained by taking an escherichia coli-bacillus licheniformis shuttle cloning vector pBE2 as a framework and cloning into a strong bacillus constitutive promoter P43 and a levansucrase signal sequence sacB which can ensure that a recombinant protein is directly secreted into a culture medium. It carries AmprAnd KmrThe gene can utilize ampicillin resistance as a selection marker in escherichia coli, and can utilize kanamycin resistance as a selection marker in bacillus subtilis and bacillus licheniformis.
2. Construction of high-Activity phospholipase D expression vector pBSA43-pldmAxB
And carrying out double enzyme digestion on the obtained high-activity phospholipase D gene and the wild-type phospholipase D gene and a Bacillus licheniformis expression vector pBSA43 respectively through EcoR I and Not I, then connecting, constructing to obtain a recombinant plasmid pBSA43-pldmAxB, transforming to escherichia coli DH5 α competent cells, selecting positive transformants, extracting the plasmid, carrying out enzyme digestion verification and sequencing, and determining that the construction is successful to obtain the recombinant strain pBSA 43-pldmAxB.
3. Expression vector pBSA43-pldmAxB transformation of Bacillus licheniformis TCCC11965
Adding 60 mu L of competent cells and 1 mu L (50 ng/mu L) of pBSA43-pldmAxB into a precooled 1mm electric rotating cup, uniformly mixing and carrying out ice bath for 5min, setting parameters (25 mu F, 200 omega, 4.5-5.0ms), shocking once, immediately adding 1mL of recovery medium (LB +0.5mol/L sorbitol +0.5mol/L mannitol), uniformly mixing, sucking into a 1.5mLEP tube, shaking and culturing for 3h at 37 ℃, centrifuging, reserving 200 mu L of recovery and coating on a resistant LB plate, culturing for 24h at 37 ℃, picking up a transformant, extracting plasmids, carrying out enzyme digestion verification (pBSA43-pldmD84I is shown in figure 3, and carrying out other mutant gene recombination plasmid recombination enzyme digestion verification as shown in figure 3), thus obtaining a bacillus licheniformis strain TCCC11965/pBSA 43-pldmSA b.
Example 6: construction of high-activity phospholipase D recombinant bacteria of bacillus amyloliquefaciens
1. Construction of expression vector pBSA43
An expression vector pBSA43 is obtained by taking an escherichia coli-bacillus amyloliquefaciens shuttle cloning vector pBE2 as a framework and cloning into a strong bacillus constitutive promoter P43 and a levansucrase signal sequence sacB which can ensure that a recombinant protein is directly secreted into a culture medium. It carries AmprAnd KmrThe gene can utilize ampicillin resistance as a selection marker in escherichia coli, and can utilize kanamycin resistance as a selection marker in bacillus subtilis and bacillus licheniformis.
2. Construction of high-Activity phospholipase D expression vector pBSA43-pldmAxB
And carrying out double enzyme digestion on the obtained high-activity phospholipase D gene and the wild-type phospholipase D gene and a bacillus amyloliquefaciens expression vector pBSA43 respectively through EcoR I and Not I, then connecting, constructing to obtain a recombinant plasmid pBSA43-pldmAxB, transforming to escherichia coli DH5 α competent cells, selecting positive transformants, extracting the plasmid, carrying out enzyme digestion verification and sequencing, and determining that the construction is successful to obtain the recombinant strain pBSA 43-pldmAxB.
3. Expression vector pBSA43-pldmAxB transformed Bacillus amyloliquefaciens CGMCC No.11218
Adding 60 mu L of competent cells and 1 mu L (50 ng/mu L) of pBSA43-pldmAxB into a precooled 1mm electric rotating cup, uniformly mixing and carrying out ice bath for 5min, setting parameters (25 mu F, 200 omega, 4.5-5.0ms), shocking once, immediately adding 1mL of recovery medium (LB +0.5mol/L sorbitol +0.5mol/L mannitol), uniformly mixing, absorbing into a 1.5mLEP tube, shaking and culturing for 3h at 37 ℃, centrifuging, reserving 200 mu L of recovery and coating on a resistant LB plate, culturing for 24h at 37 ℃, picking up a transformant, extracting plasmids, carrying out enzyme digestion verification (pBSA43-pldmD84I is shown in figure 4, and other mutant gene recombinant plasmids are shown in figure 2), and obtaining the bacillus amyloliquefaciens recombinant strain CGMCC No.11218/pBSA 43-pldmAxAB.
Example 7: expression and preparation of high-activity phospholipase D in bacillus subtilis recombinant bacteria
① Bacillus subtilis recombinant strain WB600/pBSA43-pldmAxB was inoculated into LB liquid medium containing kanamycin (50. mu.g/mL), cultured overnight at 37 ℃ at 220 r/min;
② is transferred into 50mL LB culture medium according to the inoculum size of 1%, cultured for 48h at 37 ℃ at 220r/min, centrifuged for 15min at 4000r/min, and the supernatant is collected to obtain crude enzyme solution;
③ the crude enzyme solution is first eluted with 25% saturated ammonium sulfate salt to remove impure protein, then the saturation is increased to 65%, the target protein is precipitated, after dissolution, dialysis desalination is carried out, the active component obtained after dialysis desalination is dissolved with 0.02mol/LTris-HCl (pH7.0) buffer solution, after loading, the unadsorbed protein is eluted with the same buffer solution, then the gradient elution is carried out with 0.02mol/LTris-HCl (pH7.0) buffer solution containing 0-1 mol/LNaCl, the target protein is collected, the active component obtained by ion exchange is first equilibrated with 0.02mol/L Tris-HCl (pH7.0) buffer solution containing 0.15mol/L NaCl, after loading, the gradient elution is carried out with the same buffer solution at 0.5mL/min, the purified enzyme solution is obtained, SDS-PAGE analysis is carried out to the purified enzyme solution, the result is shown in figure 5, the gel with complete decolorization is put into a gel imaging system, and image analysis software is used to carry out to analyze the purity of the target protein as 98%.
④ and freeze drying the enzyme solution to obtain high-activity phospholipase D pure enzyme powder.
The enzyme activity of the enzyme powder was determined by the method of example 2 to obtain a wild-type, pldmD84, pldmN153, pldmG270, pldmP316, pldmA452, pldmD 84/N153, pldmD 84/G270, pldmD 84/P316, pldmD 84/A452, pldmN 153/G270, pldmN 153/P316, pldmN 153/A452, pldmG 270/P316, pldmG 270/A452, pldmP 316/A452, pldmD 84/N153/G270, pldmD 84/P316, pldmD 84/N153/A452, pldmD 84/G270/P316, pldmD 84/G270/A452, pldmD 84/P452/A452, pldmD 452/A452, pldmD 452/P452, pldmU 452/P452/A452, pldmU 452/P452, pldmU 84/G153/P452, pldmU 452/P452, pldmU 84/G153/P452, pldmU 26/P153/P42.7.7, pU 42, pU/P452, pU 42.7.7.7.7/P452, pU/P42.7.7.7.7.7.7.7.7.7.7.7.7.7.7.7.7.7.80, pU/P.7.7..
Example 8: expression and preparation of high-activity phospholipase D in bacillus licheniformis recombinant bacteria
① Bacillus licheniformis recombinant strain TCCC11965/pBSA43-pldmAxB was inoculated into LB liquid medium containing kanamycin (50. mu.g/mL), cultured at 37 ℃ at 220r/min overnight;
② is transferred into 50mL LB culture medium according to the inoculum size of 1%, cultured for 48h at 37 ℃ at 220r/min, centrifuged for 15min at 4000r/min, and the supernatant is collected to obtain crude enzyme solution;
③ the enzyme protein is precipitated by fractional salting-out method, the protein precipitate is collected, dissolved, dialyzed to remove salt, and then purified enzyme solution is obtained by ion exchange chromatography and gel chromatography, the purified enzyme solution is analyzed by SDS-PAGE, the result is shown in FIG. 6, the gel with complete decolorization is photographed in a gel imaging system, and the purity of the target protein is analyzed by image analysis software, the analysis result shows that the protein purity is 96%.
④ and freeze drying the enzyme solution to obtain high-activity phospholipase D pure enzyme powder.
The enzyme activity of the enzyme powder was determined by the method of example 2 to obtain a wild-type, pldmD84, pldmN153, pldmG270, pldmP316, pldmA452, pldmD 84/N153, pldmD 84/G270, pldmD 84/P316, pldmD 84/A452, pldmN 153/G270, pldmN 153/P316, pldmN 153/A452, pldmG 270/P316, pldmG 270/A452, pldmP 316/A452, pldmD 84/N153/G270, pldmD 84/P316, pldmD 84/N153/A452, pldmD 84/G270/P316, pldmD 84/G270/A452, pldmD 84/P452/A452, pldmD 452/A452, pldmD 452/P452, pldmU 452/P452/A452, pldmU 452/P452, pldmU 84/G153/P452, pldmU 452/P452, pldmU 84/G153/P452, pldmU 26/P153/P42.80, pldmU/P452, pU 42.60/P452, pU/P452, pU/P452/P153/P42.60/P452, pU/P26.60/P153/P26, pU/P26, pU/P.
Example 9: expression and preparation of high-activity phospholipase D in bacillus amyloliquefaciens recombinant bacteria
① inoculating Bacillus amyloliquefaciens recombinant strain CGMCC No.11218/pBSA43-pldmAxB into LB liquid culture medium containing kanamycin (50 ug/mL), and culturing at 37 deg.C and 220r/min overnight;
② is transferred into 50mL LB culture medium according to the inoculum size of 1%, cultured for 48h at 37 ℃ at 220r/min, centrifuged for 15min at 4000r/min, and the supernatant is collected to obtain crude enzyme solution;
③ the enzyme protein is precipitated by fractional salting-out method, the protein precipitate is collected, dissolved, dialyzed to remove salt, and then purified enzyme solution is obtained by ion exchange chromatography and gel chromatography, the purified enzyme solution is analyzed by SDS-PAGE, the result is shown in FIG. 7, the gel with complete decolorization is photographed in a gel imaging system, and the purity of the target protein is analyzed by image analysis software, the analysis result shows that the protein purity is 98%.
④ and freeze drying the enzyme solution to obtain high-activity phospholipase D pure enzyme powder.
The enzyme activity of the enzyme powder was determined by the method of example 2 to obtain a wild-type, pldmD84, pldmN153, pldmG270, pldmP316, pldmA452, pldmD 84/N153, pldmD 84/G270, pldmD 84/P316, pldmD 84/A452, pldmN 153/G270, pldmN 153/P316, pldmN 153/A452, pldmG 270/P316, pldmG 270/A452, pldmP 316/A452, pldmD 84/N153/G270, pldmD 84/P316, pldmD 84/N153/A452, pldmD 84/G270/P316, pldmD 84/G270/A452, pldmD 84/P452/A452, pldmD 452/A452, pldmD 452/P452, pldmU 452/P452/A452, pldmU 452/P452, pldmU 84/G153/P452, pldmU 452/P452, pldmU 84/G153/P452, pldmU 26/P153/P42.7.7, pU 42 mg, pU/P452, pU 42.7.7.7.80, pU/P452, pU/P153/P452, pU/P42.7.7.7.7.7.7.7.80, pU/P.7.7.7.80, pU/P.80, pU/P.
Example 10: determination of phospholipase D Activity in fermentation broth
And (3) measuring the enzyme activity of the fermentation liquor of the phospholipase D, wherein the enzyme activities of the fermentation liquor of the high-activity phospholipase D obtained by fermentation in examples 7-9 are measured as follows:
example 11: preparation of phosphatidic acid with high-activity phospholipase D
The substrate is 1g of soybean lecithin (PC content is 90%), the substrate is dissolved in 10mL of phosphate buffer solution with pH7.0, and 50U of high-activity phospholipase D is added into each milliliter of reaction system, wherein the high-activity phospholipase D is prepared in the invention of the embodiment 7-9 (the high-activity phospholipase D can be obtained by fermenting any mutant and the addition amount of enzyme powder during catalysis can reach 50U/mL). The reaction temperature was 40 ℃ and the reaction was carried out for 12h with stirring by a magnetic stirrer, followed by extraction with 30mL of chloroform/methanol (2: 1) to obtain phosphatidic acid, which gave a conversion of 93% to phosphatidic acid, and a conversion (mol%) of PA-PA amount/initial PC amount X100%.
Example 12: preparation of PS, PE, PG and PI with high-activity phospholipase D
1g of soybean lecithin (containing 90% of PC) is respectively mixed with 2.5g of serine, 1mL of ethanolamine, 5mL of glycerol and 5mL of inositol, dissolved in 5mL of acetic acid-sodium acetate buffer solution with the pH value of 5.5, and finally mixed until the total volume is 10mL, and 100U of high-activity phospholipase D is added into each milliliter of reaction system, wherein the high-activity phospholipase D is prepared according to the invention in the embodiment 7-9 (the high-activity phospholipase D can be obtained by fermenting any mutant, and the addition amount of enzyme powder during catalysis can reach 100U/mL). The reaction temperature was 40 ℃ and the reaction was carried out for 12h with stirring by a magnetic stirrer, followed by extraction with 30mL of chloroform/methanol (2: 1) to obtain PS, PE, PG and PI, whose conversions for the preparation of PS, PE, PG and PI were 79.3%, 53.9%, 60.1%, 32.1%, respectively. Conversion (% by mole) is the amount of product/initial amount of PC x 100%.
Sequence listing
<110> Tianjin science and technology university
<120> a novel phospholipase D and a method for preparing functional phospholipid by using the same
<130>1
<141>2019-11-21
<160>14
<170>SIPOSequenceListing 1.0
<210>1
<211>1527
<212>DNA
<213> Streptomyces antibioticus (Streptomyces antibioticus)
<400>1
gcggacacac cgcccacccc ccatctggac gccatcgagc ggtcgctgcg cgacacctcc 60
cccggcctcg aaggctcggt gtggcagcgc acggacggca accgcctgga cgccccggac 120
ggcgaccccg ccggctggct gctgcagacc cccggctgct ggggcgacgc cggctgcaag 180
gaccgcgccg gcacccggcg gctgctcgac aagatgaccc gcaacatcgc cgacgcccgg 240
cacaccgtgg acatctcctc gctggccccc ttccccaacg gcgggttcga ggacgcggtc 300
gtcgacggcc tcaaggcggt cgtcgcggcg gggcactccc cgcgggtgcg catcctggtc 360
ggcgccgccc cgatctacca cctcaacgtg gtgccgtccc gctaccgcga cgagctgatc 420
ggcaagctcg gcgcggcggc cggcaaggtc acgctcaacg tcgcctcgat gaccacgtcc 480
aagacgtcgc tctcctggaa ccactccaag ctcctcgtgg tcgacgggaa gacggccatc 540
acgggcggga tcaacggctg gaaggacgac tacctcgaca ccgcccaccc ggtgtcggac 600
gtggacatgg cgctcagcgg cccggccgcc gcctcggcgg ggaagtacct cgacaccctc 660
tgggactgga cctgccgcaa cgcgtccgac ccggccaagg tgtggctcgc cacgtcgaac 720
ggcgcctcct gcatgccgtc gatggagcag gacgaggcgg gatccgcccc cgccgagccc 780
accggtgacg tccccgtcat cgcggtcggc ggcctcggcg tgggcatcaa ggagtccgac 840
ccctcctcgg gataccaccc ggacctgccg acggccccgg acaccaagtg caccgtgggg 900
ctgcacgaca acaccaacgc cgaccgcgac tacgacacgg tcaaccccga ggagaacgcg 960
ctgcgttcgc tcatcgccag cgcgcgcagc cacgtcgaga tctcccagca ggacctcaac 1020
gccacctgcc cgccgttgcc gcgctacgac atccggacct acgacaccct cgcgggcaag 1080
ctggccgccg gggtcaaggt ccgcatcgtc gtcagcgatc ccgccaaccg cggcgccgtc 1140
ggcagcgggg gctactccca gatcaagtcc ctggacgaga tcagcgacac cctccgcacg 1200
cgtctcgtcg ccctgaccgg cgacaacgag aaggcgtcgc gggccctgtg cggcaacctg 1260
cagctcgcct cgttccgcag ctcggacgcc gcgaagtggg ccgacggcaa gccgtacgcg 1320
ctgcaccaca agctggtgtc ggtggacgac tcggcgttct acatcggctc caagaacctc 1380
tacccggcct ggctgcagga cttcggctac atcgtcgaga gccccgccgc ggcccagcag 1440
ctcaagaccg agctgctcga cccggagtgg aagtactccc agcaggcggc ggccaccccg 1500
gccggctgcc cggctcgcca ggcgggc 1527
<210>2
<211>509
<212>PRT
<213> Streptomyces antibioticus (Streptomyces antibioticus)
<400>2
Ala Asp Thr Pro Pro Thr Pro His Leu Asp Ala Ile Glu Arg Ser Leu
1 5 10 15
Arg Asp Thr Ser Pro Gly Leu Glu Gly Ser Val Trp Gln Arg Thr Asp
20 25 30
Gly Asn Arg Leu Asp Ala Pro Asp Gly Asp Pro Ala Gly Trp Leu Leu
35 40 45
Gln Thr Pro Gly Cys Trp Gly Asp Ala Gly Cys Lys Asp Arg Ala Gly
50 55 60
Thr Arg Arg Leu Leu Asp Lys Met Thr Arg Asn Ile Ala Asp Ala Arg
65 70 75 80
His Thr Val Asp Ile Ser Ser Leu Ala Pro Phe Pro Asn Gly Gly Phe
85 90 95
Glu Asp Ala Val Val Asp Gly Leu Lys Ala Val Val Ala Ala Gly His
100 105 110
Ser Pro Arg Val Arg Ile Leu Val Gly Ala Ala Pro Ile Tyr His Leu
115 120125
Asn Val Val Pro Ser Arg Tyr Arg Asp Glu Leu Ile Gly Lys Leu Gly
130 135 140
Ala Ala Ala Gly Lys Val Thr Leu Asn Val Ala Ser Met Thr Thr Ser
145 150 155 160
Lys Thr Ser Leu Ser Trp Asn His Ser Lys Leu Leu Val Val Asp Gly
165 170 175
Lys Thr Ala Ile Thr Gly Gly Ile Asn Gly Trp Lys Asp Asp Tyr Leu
180 185 190
Asp Thr Ala His Pro Val Ser Asp Val Asp Met Ala Leu Ser Gly Pro
195 200 205
Ala Ala Ala Ser Ala Gly Lys Tyr Leu Asp Thr Leu Trp Asp Trp Thr
210 215 220
Cys Arg Asn Ala Ser Asp Pro Ala Lys Val Trp Leu Ala Thr Ser Asn
225 230 235 240
Gly Ala Ser Cys Met Pro Ser Met Glu Gln Asp Glu Ala Gly Ser Ala
245 250 255
Pro Ala Glu Pro Thr Gly Asp Val Pro Val Ile Ala Val Gly Gly Leu
260 265 270
Gly Val Gly Ile Lys Glu Ser Asp Pro Ser Ser Gly Tyr His Pro Asp
275 280285
Leu Pro Thr Ala Pro Asp Thr Lys Cys Thr Val Gly Leu His Asp Asn
290 295 300
Thr Asn Ala Asp Arg Asp Tyr Asp Thr Val Asn Pro Glu Glu Asn Ala
305 310 315 320
Leu Arg Ser Leu Ile Ala Ser Ala Arg Ser His Val Glu Ile Ser Gln
325 330 335
Gln Asp Leu Asn Ala Thr Cys Pro Pro Leu Pro Arg Tyr Asp Ile Arg
340 345 350
Thr Tyr Asp Thr Leu Ala Gly Lys Leu Ala Ala Gly Val Lys Val Arg
355 360 365
Ile Val Val Ser Asp Pro Ala Asn Arg Gly Ala Val Gly Ser Gly Gly
370 375 380
Tyr Ser Gln Ile Lys Ser Leu Asp Glu Ile Ser Asp Thr Leu Arg Thr
385 390 395 400
Arg Leu Val Ala Leu Thr Gly Asp Asn Glu Lys Ala Ser Arg Ala Leu
405 410 415
Cys Gly Asn Leu Gln Leu Ala Ser Phe Arg Ser Ser Asp Ala Ala Lys
420 425 430
Trp Ala Asp Gly Lys Pro Tyr Ala Leu His His Lys Leu Val Ser Val
435 440 445
Asp Asp Ser Ala Phe Tyr Ile Gly Ser Lys Asn Leu Tyr Pro Ala Trp
450 455 460
Leu Gln Asp Phe Gly Tyr Ile Val Glu Ser Pro Ala Ala Ala Gln Gln
465 470 475 480
Leu Lys Thr Glu Leu Leu Asp Pro Glu Trp Lys Tyr Ser Gln Gln Ala
485 490 495
Ala Ala Thr Pro Ala Gly Cys Pro Ala Arg Gln Ala Gly
500 505
<210>3
<211>1527
<212>DNA
<213> Artificial sequence ()
<400>3
gcggacacac cgcccacccc ccatctggac gccatcgagc ggtcgctgcg cgacacctcc 60
cccggcctcg aaggctcggt gtggcagcgc acggacggca accgcctgga cgccccggac 120
ggcgaccccg ccggctggct gctgcagacc cccggctgct ggggcgacgc cggctgcaag 180
gaccgcgccg gcacccggcg gctgctcgac aagatgaccc gcaacatcgc cgacgcccgg 240
cacaccgtga tcatctcctc gctggccccc ttccccaacg gcgggttcga ggacgcggtc 300
gtcgacggcc tcaaggcggt cgtcgcggcg gggcactccc cgcgggtgcg catcctggtc 360
ggcgccgccc cgatctacca cctcaacgtg gtgccgtccc gctaccgcga cgagctgatc 420
ggcaagctcg gcgcggcggc cggcaaggtc acgctcatcg tcgcctcgat gaccacgtcc 480
aagacgtcgc tctcctggaa ccactccaag ctcctcgtgg tcgacgggaa gacggccatc 540
acgggcggga tcaacggctg gaaggacgac tacctcgaca ccgcccaccc ggtgtcggac 600
gtggacatgg cgctcagcgg cccggccgcc gcctcggcgg ggaagtacct cgacaccctc 660
tgggactgga cctgccgcaa cgcgtccgac ccggccaagg tgtggctcgc cacgtcgaac 720
ggcgcctcct gcatgccgtc gatggagcag gacgaggcgg gatccgcccc cgccgagccc 780
accggtgacg tccccgtcat cgcggtcttc ggcctcggcg tgggcatcaa ggagtccgac 840
ccctcctcgg gataccaccc ggacctgccg acggccccgg acaccaagtg caccgtgggg 900
ctgcacgaca acaccaacgc cgaccgcgac tacgacacgg tcaactggga ggagaacgcg 960
ctgcgttcgc tcatcgccag cgcgcgcagc cacgtcgaga tctcccagca ggacctcaac 1020
gccacctgcc cgccgttgcc gcgctacgac atccggacct acgacaccct cgcgggcaag 1080
ctggccgccg gggtcaaggt ccgcatcgtc gtcagcgatc ccgccaaccg cggcgccgtc 1140
ggcagcgggg gctactccca gatcaagtcc ctggacgaga tcagcgacac cctccgcacg 1200
cgtctcgtcg ccctgaccgg cgacaacgag aaggcgtcgc gggccctgtg cggcaacctg 1260
cagctcgcct cgttccgcag ctcggacgcc gcgaagtggg ccgacggcaa gccgtacgcg 1320
ctgcaccaca agctggtgtc ggtggacgac tcgttcttct acatcggctc caagaacctc 1380
tacccggcct ggctgcagga cttcggctac atcgtcgaga gccccgccgc ggcccagcag 1440
ctcaagaccg agctgctcga cccggagtgg aagtactccc agcaggcggc ggccaccccg 1500
gccggctgcc cggctcgcca ggcgggc 1527
<210>4
<211>509
<212>PRT
<213> Artificial sequence ()
<400>4
Ala Asp Thr Pro Pro Thr Pro His Leu Asp Ala Ile Glu Arg Ser Leu
1 5 10 15
Arg Asp Thr Ser Pro Gly Leu Glu Gly Ser Val Trp Gln Arg Thr Asp
20 25 30
Gly Asn Arg Leu Asp Ala Pro Asp Gly Asp Pro Ala Gly Trp Leu Leu
35 40 45
Gln Thr Pro Gly Cys Trp Gly Asp Ala Gly Cys Lys Asp Arg Ala Gly
50 55 60
Thr Arg Arg Leu Leu Asp Lys Met Thr Arg Asn Ile Ala Asp Ala Arg
65 70 75 80
His Thr Val Ile Ile Ser Ser Leu Ala Pro Phe Pro Asn Gly Gly Phe
85 90 95
Glu Asp Ala Val Val Asp Gly Leu Lys Ala Val Val Ala Ala Gly His
100 105 110
Ser Pro Arg Val Arg Ile Leu Val Gly Ala Ala Pro Ile Tyr His Leu
115 120 125
Asn Val Val Pro Ser Arg Tyr Arg Asp Glu Leu Ile Gly Lys Leu Gly
130 135 140
Ala Ala AlaGly Lys Val Thr Leu Ile Val Ala Ser Met Thr Thr Ser
145 150 155 160
Lys Thr Ser Leu Ser Trp Asn His Ser Lys Leu Leu Val Val Asp Gly
165 170 175
Lys Thr Ala Ile Thr Gly Gly Ile Asn Gly Trp Lys Asp Asp Tyr Leu
180 185 190
Asp Thr Ala His Pro Val Ser Asp Val Asp Met Ala Leu Ser Gly Pro
195 200 205
Ala Ala Ala Ser Ala Gly Lys Tyr Leu Asp Thr Leu Trp Asp Trp Thr
210 215 220
Cys Arg Asn Ala Ser Asp Pro Ala Lys Val Trp Leu Ala Thr Ser Asn
225 230 235 240
Gly Ala Ser Cys Met Pro Ser Met Glu Gln Asp Glu Ala Gly Ser Ala
245 250 255
Pro Ala Glu Pro Thr Gly Asp Val Pro Val Ile Ala Val Phe Gly Leu
260 265 270
Gly Val Gly Ile Lys Glu Ser Asp Pro Ser Ser Gly Tyr His Pro Asp
275 280 285
Leu Pro Thr Ala Pro Asp Thr Lys Cys Thr Val Gly Leu His Asp Asn
290 295 300
Thr Asn Ala Asp ArgAsp Tyr Asp Thr Val Asn Trp Glu Glu Asn Ala
305 310 315 320
Leu Arg Ser Leu Ile Ala Ser Ala Arg Ser His Val Glu Ile Ser Gln
325 330 335
Gln Asp Leu Asn Ala Thr Cys Pro Pro Leu Pro Arg Tyr Asp Ile Arg
340 345 350
Thr Tyr Asp Thr Leu Ala Gly Lys Leu Ala Ala Gly Val Lys Val Arg
355 360 365
Ile Val Val Ser Asp Pro Ala Asn Arg Gly Ala Val Gly Ser Gly Gly
370 375 380
Tyr Ser Gln Ile Lys Ser Leu Asp Glu Ile Ser Asp Thr Leu Arg Thr
385 390 395 400
Arg Leu Val Ala Leu Thr Gly Asp Asn Glu Lys Ala Ser Arg Ala Leu
405 410 415
Cys Gly Asn Leu Gln Leu Ala Ser Phe Arg Ser Ser Asp Ala Ala Lys
420 425 430
Trp Ala Asp Gly Lys Pro Tyr Ala Leu His His Lys Leu Val Ser Val
435 440 445
Asp Asp Ser Phe Phe Tyr Ile Gly Ser Lys Asn Leu Tyr Pro Ala Trp
450 455 460
Leu Gln Asp Phe Gly Tyr IleVal Glu Ser Pro Ala Ala Ala Gln Gln
465 470 475 480
Leu Lys Thr Glu Leu Leu Asp Pro Glu Trp Lys Tyr Ser Gln Gln Ala
485 490 495
Ala Ala Thr Pro Ala Gly Cys Pro Ala Arg Gln Ala Gly
500 505
<210>5
<211>24
<212>DNA
<213> Artificial sequence ()
<400>5
ccggaattcg gcggacacac cgcc 24
<210>6
<211>30
<212>DNA
<213> Artificial sequence ()
<400>6
aaggaaaaaa gcggccgcgc ccgcctggcg 30
<210>7
<211>27
<212>DNA
<213> Artificial sequence ()
<400>7
cggcaaggtc acgctcatcg tcgcctc 27
<210>8
<211>27
<212>DNA
<213> Artificial sequence ()
<400>8
gaggcgacga tgagcgtgac cttgccg 27
<210>9
<211>25
<212>DNA
<213> Artificial sequence ()
<400>9
tccccgtcat cgcggtcttc ggcct 25
<210>10
<211>25
<212>DNA
<213> Artificial sequence ()
<400>10
aggccgaaga ccgcgatgac gggga 25
<210>11
<211>32
<212>DNA
<213> Artificial sequence ()
<400>11
tacgacacgg tcaactggga ggagaacgcg ct 32
<210>12
<211>32
<212>DNA
<213> Artificial sequence ()
<400>12
agcgcgttct cctcccagtt gaccgtgtcg ta 32
<210>13
<211>39
<212>DNA
<213> Artificial sequence ()
<400>13
ggtggacgac tcgttcttct acatcggctc caagaacct 39
<210>14
<211>39
<212>DNA
<213> Artificial sequence ()
<400>14
aggttcttgg agccgatgta gaagaacgag tcgtccacc 39
Claims (7)
1. A phospholipase D mutant, characterized in that, based on the phospholipase D amino acid sequence shown in SEQ ID No.2,
wherein at least one amino acid at positions 84, 153, 270, 316 and 452 is mutated as follows:
at position 84: asp 84 Ile;
153 th bit: asn 153 Ile;
270 th position: gly270 Phe;
316 th bit: pro316 Trp;
at bit 452: ala452 Phe.
2. The phospholipase D mutant of claim 1 which encodes the gene.
3. The gene encoding the phospholipase D mutant according to claim 2, wherein the gene is represented by SEQ ID No.3 of the sequence Listing.
4. Use of the phospholipase D mutant according to claim 1 or the gene according to claim 2, in the preparation of phosphatidic acid, phosphatidylserine, phosphatidylethanolamine, phosphatidylglycerol and phosphatidylinositol.
5. A recombinant vector or recombinant bacterium comprising the gene of claim 2.
6. The expression vector or host cell of claim 5, wherein the expression vector is pBSA43 and the host cell is Bacillus subtilis WB 600; the expression vector is pBSA43, and the host cell is Bacillus amyloliquefaciens CGMCC No. 11218; the expression vector is pBSA43, and the host cell is Bacillus licheniformis TCCC 11965.
7. The method for producing a mutant of phospholipase D as set forth in claim 1, comprising the steps of:
(1) carrying out enzyme digestion on the gene of claim 2, and connecting the gene with an expression vector to obtain a new recombinant vector;
(2) and transforming the recombinant vector into a host cell to obtain a recombinant strain, and fermenting the recombinant strain to obtain the high-activity phospholipase D.
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210528699.3A CN114891764B (en) | 2019-11-21 | 2019-11-21 | Phospholipase, gene thereof, engineering bacteria and preparation method |
| CN202210528697.4A CN115161303B (en) | 2019-11-21 | 2019-11-21 | Phospholipase mutant and method for synthesizing glycerophospholipids by using phospholipase mutant |
| CN201911149105.2A CN110904072B (en) | 2019-11-21 | 2019-11-21 | Novel phospholipase D and method for preparing functional phospholipid by using same |
| CN202210530392.7A CN114908070A (en) | 2019-11-21 | 2019-11-21 | Phospholipase and method for preparing glycerophospholipid by using same |
| CN202210530395.0A CN114891765B (en) | 2019-11-21 | 2019-11-21 | Phospholipase and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911149105.2A CN110904072B (en) | 2019-11-21 | 2019-11-21 | Novel phospholipase D and method for preparing functional phospholipid by using same |
Related Child Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210530395.0A Division CN114891765B (en) | 2019-11-21 | 2019-11-21 | Phospholipase and application thereof |
| CN202210530392.7A Division CN114908070A (en) | 2019-11-21 | 2019-11-21 | Phospholipase and method for preparing glycerophospholipid by using same |
| CN202210528699.3A Division CN114891764B (en) | 2019-11-21 | 2019-11-21 | Phospholipase, gene thereof, engineering bacteria and preparation method |
| CN202210528697.4A Division CN115161303B (en) | 2019-11-21 | 2019-11-21 | Phospholipase mutant and method for synthesizing glycerophospholipids by using phospholipase mutant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110904072A true CN110904072A (en) | 2020-03-24 |
| CN110904072B CN110904072B (en) | 2022-06-21 |
Family
ID=69818349
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911149105.2A Active CN110904072B (en) | 2019-11-21 | 2019-11-21 | Novel phospholipase D and method for preparing functional phospholipid by using same |
| CN202210530395.0A Active CN114891765B (en) | 2019-11-21 | 2019-11-21 | Phospholipase and application thereof |
| CN202210530392.7A Pending CN114908070A (en) | 2019-11-21 | 2019-11-21 | Phospholipase and method for preparing glycerophospholipid by using same |
| CN202210528699.3A Active CN114891764B (en) | 2019-11-21 | 2019-11-21 | Phospholipase, gene thereof, engineering bacteria and preparation method |
| CN202210528697.4A Active CN115161303B (en) | 2019-11-21 | 2019-11-21 | Phospholipase mutant and method for synthesizing glycerophospholipids by using phospholipase mutant |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210530395.0A Active CN114891765B (en) | 2019-11-21 | 2019-11-21 | Phospholipase and application thereof |
| CN202210530392.7A Pending CN114908070A (en) | 2019-11-21 | 2019-11-21 | Phospholipase and method for preparing glycerophospholipid by using same |
| CN202210528699.3A Active CN114891764B (en) | 2019-11-21 | 2019-11-21 | Phospholipase, gene thereof, engineering bacteria and preparation method |
| CN202210528697.4A Active CN115161303B (en) | 2019-11-21 | 2019-11-21 | Phospholipase mutant and method for synthesizing glycerophospholipids by using phospholipase mutant |
Country Status (1)
| Country | Link |
|---|---|
| CN (5) | CN110904072B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112322602A (en) * | 2020-11-03 | 2021-02-05 | 江南大学 | Method for promoting extracellular expression of protein in bacillus subtilis by coexpression phospholipase |
| CN112813090A (en) * | 2020-12-31 | 2021-05-18 | 河南省商业科学研究所有限责任公司 | Heterologous expression recombinant plasmid of phospholipase D and construction method thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116024196A (en) * | 2022-11-25 | 2023-04-28 | 广西科学院 | Lipase mutant and application thereof |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2220459A1 (en) * | 1995-06-07 | 1996-12-19 | Cadus Pharmaceutical Corporation | Expression of functional vertebrate phospholipases in yeast |
| AU3820402A (en) * | 1997-01-31 | 2002-06-20 | Odyssey Thera, Inc. | Protein fragment complementation assays to detect biomolecular interactions |
| JP2005080519A (en) * | 2003-09-04 | 2005-03-31 | Okayama Prefecture | Method for stabilizing phospholipase d |
| WO2007089038A1 (en) * | 2006-02-02 | 2007-08-09 | National University Corporation Nagoya University | Novel phospholipase d |
| JP2009072152A (en) * | 2007-09-21 | 2009-04-09 | Univ Nagoya | Method for producing natural type phosphatidylinositol and modified phospholipase d therefor |
| CN108841770A (en) * | 2018-07-06 | 2018-11-20 | 江南大学 | A kind of bacillus subtilis engineering bacteria that can express phospholipase D |
| CN109022390A (en) * | 2018-07-27 | 2018-12-18 | 厦门大学 | A method of isolating and purifying Escherichia coli recombination phospholipase D |
| CN109136207A (en) * | 2018-07-27 | 2019-01-04 | 厦门大学 | A kind of method of recombination bacillus coli production phospholipase D |
| CN110283803A (en) * | 2016-06-02 | 2019-09-27 | 天津科技大学 | A kind of novel phospholipase D and its method for preparing phosphatidic acid, phosphatidylserine |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2191624C (en) * | 1995-03-29 | 2006-08-08 | Shinji Morioka | Dna fragment, recombinant vector containing the same and method for expressing foreign genes using the same |
| CN1235636A (en) * | 1996-10-31 | 1999-11-17 | 诺沃挪第克公司 | Phospholipase, production and use thereof |
| EP1325117A2 (en) * | 2000-10-06 | 2003-07-09 | Incyte Genomics, Inc. | Lipid metabolism enzymes |
| EP1985697A1 (en) * | 2007-04-27 | 2008-10-29 | AM-Pharma B.V. | Modified phosphatases |
| CN108949721B (en) * | 2018-07-27 | 2020-06-05 | 江南大学 | Recombinant strain for expressing phospholipase D and application |
| CN109943546B (en) * | 2019-04-12 | 2021-08-03 | 天津科技大学 | Glutamine transaminase mutant and preparation method and application thereof |
-
2019
- 2019-11-21 CN CN201911149105.2A patent/CN110904072B/en active Active
- 2019-11-21 CN CN202210530395.0A patent/CN114891765B/en active Active
- 2019-11-21 CN CN202210530392.7A patent/CN114908070A/en active Pending
- 2019-11-21 CN CN202210528699.3A patent/CN114891764B/en active Active
- 2019-11-21 CN CN202210528697.4A patent/CN115161303B/en active Active
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2220459A1 (en) * | 1995-06-07 | 1996-12-19 | Cadus Pharmaceutical Corporation | Expression of functional vertebrate phospholipases in yeast |
| AU3820402A (en) * | 1997-01-31 | 2002-06-20 | Odyssey Thera, Inc. | Protein fragment complementation assays to detect biomolecular interactions |
| JP2005080519A (en) * | 2003-09-04 | 2005-03-31 | Okayama Prefecture | Method for stabilizing phospholipase d |
| WO2007089038A1 (en) * | 2006-02-02 | 2007-08-09 | National University Corporation Nagoya University | Novel phospholipase d |
| CN101379187A (en) * | 2006-02-02 | 2009-03-04 | 国立大学法人名古屋大学 | Novel phospholipase D |
| JP2009072152A (en) * | 2007-09-21 | 2009-04-09 | Univ Nagoya | Method for producing natural type phosphatidylinositol and modified phospholipase d therefor |
| CN110283803A (en) * | 2016-06-02 | 2019-09-27 | 天津科技大学 | A kind of novel phospholipase D and its method for preparing phosphatidic acid, phosphatidylserine |
| CN108841770A (en) * | 2018-07-06 | 2018-11-20 | 江南大学 | A kind of bacillus subtilis engineering bacteria that can express phospholipase D |
| CN109022390A (en) * | 2018-07-27 | 2018-12-18 | 厦门大学 | A method of isolating and purifying Escherichia coli recombination phospholipase D |
| CN109136207A (en) * | 2018-07-27 | 2019-01-04 | 厦门大学 | A kind of method of recombination bacillus coli production phospholipase D |
Non-Patent Citations (5)
| Title |
|---|
| ATSUSHI MASAYAMA等: "Streptomyces phospholipase D mutants with altered substrate specificity capable of phosphatidylinositol synthesis", 《CHEMBIOCHEM》 * |
| MASAYAMA, ATSUSHI等: "Isolation of Phospholipase D Mutants Having Phosphatidylinositol-Synthesizing Activity with Positional Specificity on myo-Inositol", 《CHEMBIOCHEM》 * |
| XIONG,W.: "phospholipase D, partial [synthetic construct]", 《GENBANK DATABASE》 * |
| 徐银凤等: "蜡状芽孢杆菌磷脂酶D的活性形式及HKD活性区域的分子改造对其活性的影响", 《中国生物化学与分子生物学报》 * |
| 李斌等: "色褐链霉菌磷脂酶D基因pld的克隆与表达", 《化学与生物工程》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112322602A (en) * | 2020-11-03 | 2021-02-05 | 江南大学 | Method for promoting extracellular expression of protein in bacillus subtilis by coexpression phospholipase |
| CN112813090A (en) * | 2020-12-31 | 2021-05-18 | 河南省商业科学研究所有限责任公司 | Heterologous expression recombinant plasmid of phospholipase D and construction method thereof |
| CN112813090B (en) * | 2020-12-31 | 2024-02-06 | 河南省商业科学研究所有限责任公司 | Heterologous expression recombinant plasmid of phospholipase D and construction method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114891764B (en) | 2023-09-01 |
| CN115161303A (en) | 2022-10-11 |
| CN114908070A (en) | 2022-08-16 |
| CN114891765A (en) | 2022-08-12 |
| CN110904072B (en) | 2022-06-21 |
| CN114891765B (en) | 2023-12-19 |
| CN115161303B (en) | 2024-02-13 |
| CN114891764A (en) | 2022-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110129298B (en) | Phospholipase D mutant and application thereof | |
| CN110904072B (en) | Novel phospholipase D and method for preparing functional phospholipid by using same | |
| US11377674B2 (en) | Recombinant strain expressing phospholipase D and application thereof | |
| CN109576244B (en) | Novel lipase, preparation and application thereof | |
| CN109321586A (en) | Recombinant Aspergillus niger Glucose Oxidase optimization gene and its expression vector and application | |
| CN113862233A (en) | Method for improving acid stability of glucose oxidase, mutant Q241E/R499E, gene and application | |
| CN112111472B (en) | Novel beta-xylosidase and preparation thereof | |
| CN104928272A (en) | Fusion polypeptide, nucleic acid molecule encoding the same, and method for producing itaconic acid using the same | |
| CN112746067A (en) | Lysine decarboxylase mutants for producing D-ornithine | |
| CN110283797B (en) | Tyrosinase, gene, engineering bacterium and preparation method thereof | |
| CN111748535B (en) | Alanine dehydrogenase mutant and application thereof in fermentation production of L-alanine | |
| CN114262695B (en) | Saccharomyces cerevisiae engineering bacterium for producing CBGA precursor and construction method and application thereof | |
| CN112410353B (en) | fkbS gene, genetic engineering bacterium containing fkbS gene, and preparation method and application of fkbS gene | |
| KR101551533B1 (en) | Recombinant microorganism having enhanced butanediol producing ability and method for producing butanediol using the same | |
| CN114438057B (en) | Heat-resistant alkali-resistant xylanase and application thereof | |
| CN113046289B (en) | Method for efficiently expressing lipase in bacillus subtilis | |
| CN112342203B (en) | Application of ribosome sigma factor, mutant thereof and protein obtained by encoding to increase yield of lipstatin | |
| JP7492817B2 (en) | Monoacylglycerol lipase variant and method for producing same | |
| KR102016050B1 (en) | Novel promoter and uses thereof | |
| KR101713885B1 (en) | Lipase with sn-1 specificity and method for production thereof | |
| CN116121215A (en) | Mutant of glycerophosphate oxidase and application thereof | |
| CN114540397A (en) | Method for enhancing expression of regulatory protein to improve fermentation level of glutamine transaminase | |
| CN111363733A (en) | Heat-resistant phospholipase D mutant and preparation method thereof and method for synthesizing functional phospholipid | |
| CN112522231A (en) | Acyltransferase, and coding gene and application thereof | |
| CN115927264A (en) | Keratinase, compound enzyme preparation of keratinase, eucommia ulmoides leaf extract and bile acid and application of compound enzyme preparation in preparation of animal breeding feed |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |